Newer Technologies for Ocular Drug Development and Deployment

Publication type: Book Chapter
Publication date: 2019-09-01
Springer Nature
SJR: —
CiteScore: —
Impact factor: —
ISSN: 25233807, 25233815
Abstract
There are around 285 million visually impaired people in the world with 39 million blind and 256 million with low vision. The main disorders responsible for this disease burden are age-related macular degeneration (AMD), diabetic retinopathy/macular edema (DR/DME), and glaucoma. There are several effective medications that are used to treat these conditions, but it is still a challenge to provide this treatment with a sustained release profile, minimum side effects, and cost-effective rates. In this chapter we will review the ocular drug development process and highlight developments that can potentially improve the efficiency of the current ocular drug discovery industry.
Found 

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
0
Share
Cite this
GOST |
Cite this
GOST Copy
Thakur S. Newer Technologies for Ocular Drug Development and Deployment // Current Advances in Ocular Surgery. 2019. pp. 125-131.
GOST all authors (up to 50) Copy
Thakur S. Newer Technologies for Ocular Drug Development and Deployment // Current Advances in Ocular Surgery. 2019. pp. 125-131.
RIS |
Cite this
RIS Copy
TY - GENERIC
DO - 10.1007/978-981-13-9795-0_8
UR - https://doi.org/10.1007/978-981-13-9795-0_8
TI - Newer Technologies for Ocular Drug Development and Deployment
T2 - Current Advances in Ocular Surgery
AU - Thakur, Sahil
PY - 2019
DA - 2019/09/01
PB - Springer Nature
SP - 125-131
SN - 2523-3807
SN - 2523-3815
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@incollection{2019_Thakur,
author = {Sahil Thakur},
title = {Newer Technologies for Ocular Drug Development and Deployment},
publisher = {Springer Nature},
year = {2019},
pages = {125--131},
month = {sep}
}